Melanie McMillan

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target

R. Moritz, Lan Huang, Fernando Salangsang, 2022, bioRxiv.

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

M. Exline, J. Christman, K. Delucchi, 2019, The Lancet. Respiratory medicine.

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

B. Thompson, A. Leavitt, M. Matthay, 2015, The Lancet. Respiratory medicine.

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome

K. Delucchi, B. Thompson, A. Leavitt, 2014, Annals of Intensive Care.